GLP-1RA reduces risk of CV events associated with overweight and obesity
An option for lowering BP beyond prescribing an additional pill
Florian Rader, MD
Long-term durability of BP control with renal denervation
Michael Bloch, MD
Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine
Andrew Bellinger, MD, PhD
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
Michael Lincoff, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.